A detailed history of True Wealth Design, LLC transactions in Biocryst Pharmaceuticals Inc stock. As of the latest transaction made, True Wealth Design, LLC holds 39 shares of BCRX stock, worth $285. This represents 0.0% of its overall portfolio holdings.

Number of Shares
39
Previous 103 62.14%
Holding current value
$285
Previous $923,000 67.82%
% of portfolio
0.0%
Previous 0.0%

Shares

5 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Oct 21, 2025

SELL
$7.55 - $9.06 $483 - $579
-64 Reduced 62.14%
39 $297,000
Q2 2025

Aug 06, 2025

SELL
$6.41 - $11.19 $7,339 - $12,812
-1,145 Reduced 91.75%
103 $923,000
Q1 2025

May 13, 2025

BUY
$7.06 - $9.39 $6,784 - $9,023
961 Added 334.84%
1,248 $9.36 Million
Q4 2024

Feb 14, 2025

SELL
$7.03 - $8.43 $3,529 - $4,231
-502 Reduced 63.62%
287 $2.16 Million
Q3 2024

Nov 14, 2024

BUY
$6.41 - $8.69 $5,057 - $6,856
789 New
789 $6 Million

Others Institutions Holding BCRX

About BIOCRYST PHARMACEUTICALS INC


  • Ticker BCRX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 185,944,992
  • Market Cap $1.36B
  • Description
  • BioCryst Pharmaceuticals, Inc., a biotechnology company, discovers novel, oral, and small-molecule medicines. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat...
More about BCRX
Track This Portfolio

Track True Wealth Design, LLC Portfolio

Follow True Wealth Design, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of True Wealth Design, LLC, based on Form 13F filings with the SEC.

News

Stay updated on True Wealth Design, LLC with notifications on news.